Skip to main content


  • Poster presentation
  • Open Access

PB.14: Visibility of screen-detected invasive carcinoma on digital breast tomosynthesis: do we need two views?

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Breast Cancer Research201315 (Suppl 1) :P14

  • Published:


  • Breast Cancer
  • Cancer Screening
  • Breast Carcinoma
  • Invasive Carcinoma
  • Breast Density


Digital breast tomosynthesis (DBT) increases the sensitivity and specificity of detecting invasive breast carcinoma. Integration into screening raises questions. Should we perform two-view full-field digital mammography (FFDM) and two-view DBT or two-view FFDM and single-view DBT at every screening? DBT is shown to offer greatest benefit in the assessment of a soft tissue lesion. We routinely use two-view DBT in combination mode for all patients recalled from screening for a soft tissue abnormality. The aim of our study is to assess the need for two-view DBT in the detection of breast cancer.


We retrospectively queried our histopathology database for all screen-detected invasive cancers between 2011 and 2012. The study sample was 254 cases. Comparisons were made between the visibility of the cancer on MLO/CC DBT and histological type/grade, molecular profile and breast density (BIRADS).


The mean age was 59 years. In total, 4/254 cancers were visible on one-view DBT (1.6%). (Two seen on MLO DBT [spiculated masses] and two seen only on the CC view [distortions]). A total of 11/254 had greater visibility on one view in comparison with the other view on DBT (4.3%). Two of 254 cases were occult on FFDM and DBT. Recall was for clinical symptoms, both lobular invasive carcinoma (0.79%). There was no relationship between histological type, grade or molecular characteristics and the visibility on one-view versus two-view DBT.


A total 98.4% of cancers were seen on two-view FFDM and MLO-DBT. Integration of MLO-DBT into breast cancer screening with two-view FFDM is a consideration.

Authors’ Affiliations

Kings College Hospital, London, UK


© Abeyakoon et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.